Systemic sclerosis following human cytomegalovirus infection

C Ferri, M Cazzato, D Giuggioli, M Sebastiani, C Magro

Ann Rheum Dis 2002;61:937–938

Systemic sclerosis (SSc) is a connective tissue disease characterised by skin and visceral organ involvement. The cause of SSc is still unknown; it has been suggested that one or more factors may be responsible for the disease through a complex pathogenic mechanism. Immune system dysregulation, collagen hyperproduction by altered fibroblasts, and vascular alterations can variably contribute to SSc development. The presence of Raynaud’s phenomenon and diffuse microangiopathy suggests that endothelial injury may represent the first step in the pathogenesis of the disease. Among these, human cytomegalovirus (HCMV) infection may play a part in the pathogenesis of the SSc owing to its ability to infect both endothelial and monocyte/macrophage cells.

CASE REPORT

Here, we describe the case of a 33 year old women developing SSc after a recent episode of acute HCMV infection. Her past medical history was unremarkable; of interest, the patient’s mother was affected by systemic lupus erythematosus. Two months after an accidental exposure to sewer waters, the patient had a high fever, malaise, myalgias, lymphadenopathy, and a cutaneous rash. In February 2000 she was admitted to another hospital where she completely recovered within three weeks. At that time serum anti-HCMV antibodies of IgM isotype (Abbott Laboratories) were detected. Two months later, the patient developed weakness, polyarthralgias, Raynaud’s phenomenon, and ischaemic lesions to the fingertips. In June 2000 she was first referred to our rheumatology unit, where a diagnosis of SSc was made based on the following findings: cutaneous hypermelanosis, sclerodactyly, puffy hands with pitting scars to fingertips, oesophageal dysmotility, mild interstitial lung disease, a scleroderma pattern at nailfold capillaroscopic examination (enlargement and loss of capillaries), and circulating antinuclear antibodies with antinucleolar pattern at indirect immunofluorescence on Hep2 cells (table 1). In addition, SSc was classified as the limited cutaneous variant according to currently accepted criteria. Virological investigations confirmed the presence of serum anti-HCMV antibodies, IgM type, followed one month later by seroconversion (anti-HCMV, IgG type). Moreover, the presence of HCMV RNA was demonstrated by an in situ hybridisation technique in the skin biopsy specimen, showing nuclear and cytoplasmic endothelial cell and eccrine ductular cell localisation (fig 1).

During the two year follow up the patient’s clinical condition progressively worsened because of recurrent skin ulcers at the fingers, partly responsive to prostacyclin analogue (iloprost) infusion treatment.

DISCUSSION

This is the first observation of SSc following recent HCMV infection. The appearance of SSc shortly after an acute episode of viral infection suggests a possible triggering role for HCMV.
The presence of HCMV sequences within endothelial and epithelial cells may be responsible for viral lytic effect, directly and/or through HCMV driven autoimmune reaction. 

Circulating IgG autoantibodies which can bind the HCMV late protein UL94 and induce apoptosis of endothelial cells have been recently demonstrated in patients with SSc. The HCMV seems to be able to trigger a host antiviral response responsible for specific autoantibodies cross reacting with endothelial autoantigens. This molecular mimicry mechanism had been also suggested for different disorders characterised by diffuse vascular disease, including SSc. 

The HCMV driven autoimmunity may be crucial in the cascade of events leading to typical SSc alterations—namely, endothelial cell injury and consequent up regulation of fibrogenic cytokines. A possible contribution of other cofactors, can also be taken in account; among these, the familial predisposition to autoimmune disorders, as seen in our patient.

Authors’ affiliations
C Ferri, M Cazzato, D Giuggioli, M Sebastiani, Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa Italy
C Magro, Ohio State University Medical Center, Columbus, OH, USA
Correspondence to: Professor C Ferri, Dipartimento Medicina Interna, Reumatologia, Via Roma 67, 56126 Pisa, Italy; c.ferri@int.med.unipi.it
Accepted 24 April 2002

A case of orbital myositis associated with rheumatoid arthritis

S Nabili, D W McCarey, B Browne, H A Capell

CASE REPORT
A 51 year old woman with a 34 year history of seropositive, erosive, nodular rheumatoid arthritis (RA) complained of non-specific headache and diplopia of insidious onset at a routine appointment with her ophthalmologist. Her RA was generally well controlled with sulfasalazine 2 g daily, which she had taken for four years. Other drugs were bendroflumetazide 2.5 mg and atenolol 50 mg daily for hypertension along with hypromellose eye drops for dry eyes. She had no other medical history of note. She had previously been treated with intramuscular gold from 1977 until 1985 and with auranofin daily but the thyroxine level was borderline at 146 nmol/l (normal 55–144). She remained seropositive for rheumatoid factor and had a positive antinuclear antibody with a titre of 1/40. This had been positive before initiation of sulfasalazine treatment. The MR scan showed no intracranial abnormality, but there was gross enlargement of the belly of the right medial rectus

REFERENCES
which measured 1 cm in diameter (fig 1B). There was less thickening of the other extraocular muscles. A high signal was seen in these muscles on T1 weighted imaging, indicating oedema and acute inflammation.

A diagnosis of orbital myositis (OM) was made and treatment was started with oral prednisolone 60 mg daily. Her symptoms rapidly improved and steroid treatment was withdrawn within three months. Five months after her diagnosis she had mild restriction of horizontal movements in the right eye and repeat MR scan showed an element of chronic fibrosis.

DISCUSSION

OM is characterised by the onset of painful and limited extraocular movements, diplopia, ptosis, swelling of the lid, and localised chemosis and injection over the insertion of the inflamed muscle.1

The most commonly affected muscles are the superior complexes and the medial rectus muscle. OM may attack more than one muscle, and may be bilateral or recurrent.

The major differential diagnosis is thyroid ophthalmopathy. However, dysthyroid myopathy is usually painless in onset, symmetrical, slowly progressive, and associated with systemic manifestations of Grave’s disease. Lid retraction, limitation of the movement opposite to the affected muscle, and deterioration of visual function (colour vision, visual field, and visual acuity) may also occur in thyroid eye disease, in contrast with OM. Additional diseases that should be considered in the differential diagnosis include orbital cellulitis, metastasis, Tolosa-Hunt syndrome, trochleitis, and infectious myositis due to trichinosis.2

Imaging of the orbit in OM shows diffuse enlargement of the extraocular muscles, which exhibit slightly blurred margins.

Associations with OM include distant inflammatory disease such as Crohn’s disease,3 Lyme disease,4 and Wegener’s granulomatosis.3 It may also be a manifestation of a paraneoplastic syndrome.4 Although there are published reports of OM associated with psoriatic arthropathy5 and systemic lupus erythematosus,6 there has only been one case reported in association with RA.6 Management is with corticosteroids and the rapid response is almost diagnostic.

AUTHORS’ AFFILIATIONS

S Nobili, Ophthalmology Department, Gartnavel General Hospital, Glasgow, UK
D W McCarey, H A Capell, Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, UK
B Browne, Ophthalmology Department, Glasgow Royal Infirmary, Glasgow, UK

Correspondence to: Dr D W McCarey, Centre for Rheumatic Diseases, Glasgow Royal Infirmary, 84 Castle Street, Glasgow G4 0SF, UK; gc2766@clinmed.gla.ac.uk

Accepted 27 May 2002

REFERENCES


Stiff man syndrome presenting with low back pain

A Bastin, V Gurmin, R Mediwake, J Gibbs, H Beynon

Stiff man syndrome (SMS) is a rare, disabling neurological disorder characterised by progressive muscle rigidity and painful episodic spasms of the axial and proximal limb muscles. Diagnosis is based on the recognition of typical clinical features and characteristic EMG findings.7 However, although it is well described, SMS is probably underdiagnosed because of a lack of awareness of its clinical manifestations. It may present to a range of specialties and should be considered in all patients with unexplained back pain, stiffness, and muscle spasms. We present a typical case of stiff man syndrome in a patient who was referred to our unit, having previously been seen by a number of doctors and a neurosurgeon, without a diagnosis.

CASE REPORT

A 42 year old man with a 28 year history of insulin dependent diabetes mellitus (IDDM) and a two year history of progressive pain and stiffness affecting his lower back and abdomen was seen in the rheumatology clinic. He also had painful, intermittent muscle spasms. His functional ability had significantly decreased and he complained of extreme difficulties in performing tasks requiring back flexion. Bladder and bowel function was normal. Blood sugars were controlled with insulin and he had no diabetic complications.

On examination, he had a marked lumbar lordosis, a prominent thoracic kyphosis, and a protuberant abdomen (fig 1). There was pronounced paraspinall and abdominal wall muscle rigidity. Neurological examination was otherwise normal. Blood tests showed a mildly raised haemoglobin A1c (7.4) and plain radiography of the spine confirmed the clinical findings. The EMG was classical for SMS and showed sustained motor unit activity in agonist and antagonist axial and limb muscles, despite the patient’s attempts at relaxation. The diagnosis was supported by the detection of antibodies against glutamic acid decarboxylase (GAD) in his serum. His condition only mildly improved with baclofen 80 mg/day, and diazepam has now been introduced.


www.annrheumdis.com
DISCUSSION

SMS has an insidious onset, usually in the fourth or fifth decades, with progressive muscle rigidity and episodic spasms affecting the axial and limb muscles. Muscle rigidity can lead to contractures, and simultaneous contraction of the thoraco-lumbar paraspinal and abdominal wall muscles causes lumbar hyperlordosis. Episodic muscle spasms are classical in SMS and their absence should raise suspicions about the accuracy of the diagnosis. The spasms, which are often provoked by emotional upset or sudden movement, can be extremely painful, generating forces capable of fracturing long bones. R rigidity and spasms gradually impair voluntary movements and postural reflexes, resulting in slow, restricted movements and an increased risk of falls. Intellect is not affected, and motor and sensory nerve examination is also normal. However, almost all patients have an abnormal EMG pattern, which shows continuous motor unit activity in affected muscles.

The cause of SMS is unknown, but an autoimmune pathogenesis is suggested by the presence of autoantibodies and its strong association with autoimmune conditions, such as IDDM and thyroiditis. Antibodies against GAD are present in about 60% of patients with SMS. GAD is the rate limiting enzyme in the synthesis of γ-aminobutyric acid (GABA), one of the main inhibitory central neurotransmitters. Reductions in GABA production may therefore impair transmission at central nervous system inhibitory synapses, resulting in the continuous motor unit activity seen in this disease. Antibodies against amphiphysin, a nerve terminal protein, have been detected in up to 5% of anti-GAD negative patients. They are strongly associated with paraneoplastic SMS and their presence should prompt careful investigation to exclude malignancy, particularly breast cancer. However, approximately 40% of patients have no evidence of autoantibodies, suggesting that the pathogenesis of this syndrome may be heterogeneous.

Drugs that enhance GABA-mediated central inhibition, such as diazepam (up to 300 mg/day), baclofen, sodium valproate, and vigabatrin, are the mainstay of treatment for this previously refractory disease. Immunomodulatory treatments have also been used and favourable responses to corticosteroids, plasmapheresis, and intravenous immunoglobulin have been reported. Physiotherapy is also important, offering a valuable adjunct to drug treatment.

SMS should be considered in all patients with unexplained back pain, stiffness and muscle spasms as early recognition and therapeutic intervention can significantly decrease morbidity and improve quality of life.

Figure 1 Patient with stiff man syndrome.

REFERENCES

A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies

R Burgos-Vargas, J Vázquez-Mellado, C Pacheco-Tena, A Hernández-Garduño, M V Goycochea-Robles

J uvenile onset spondyloarthropathies (SpA) comprise a group of conditions, characterised by recurrent episodes of arthritis and enthesitis that may lead to structural changes and functional impairment.¹ Except for mild to moderate cases, the efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) appears limited and glucocorticoids may induce severe adverse events. According to open trials,² sulphasalazine (SSZ) appears to be a good alternative for treating juvenile onset SpA. Consequently, we conducted a phase III, exploratory, 26 week prospective, randomised, double blind, placebo controlled trial of SSZ in active juvenile onset SpA.

PATIENTS AND METHODS

Patients with the seronegative enthesopathy and arthropathy syndrome (SEA)³ or ankylosing spondylitis (AS)⁴ (onset age 16 years; current age 20 years) fulfilling the three following criteria despite stable NSAID treatment in the previous four weeks were enrolled in the trial: (a) >4 active joints; (b) ≥3 tender entheses; and (c) erythrocyte sedimentation rate (ESR) ≥25 mm/1st h. Exclusion criteria were diarrhoea, inflammatory bowel disease, mucositis, psoriasis, previous use of SSZ, sulphonamide or salicylates hypersensitivity, and concomitant diseases. The study was approved by the Institutional Review Board and parents and patients signed an informed consent. The study was formed monthly. Recruitment lasted 18 months.

Patient allocation into the group receiving SSZ or placebo was generated through a random number table; randomisation was restricted by blocks of four (ratio 1:1). Baseline versus final values were analysed by paired t test or Wilcoxon’s signed rank, and SSZ versus placebo by t test or Mann-Whitney test. The significance level was fixed at p<0.05.

Thirty three patients (27 male, six female; mean age 15.9 (SD 3.9) years; 20 with SEA syndrome, 13 with AS) received sulfasalazine (n=17) or placebo (n=16) in numbered containers according to the next available number. Except for the investigators, all study personnel were unaware of the treatment assignment. Recruitment lasted 18 months.

Daily doses of SSZ and placebo escalated from two tablets in the first week and three in the second to four tablets in the third week. Children weighing less than 30 kg received 30–60 mg/kg/day from the first to the third week.

Patients were allowed to continue receiving stable doses of NSAIDs or prednison (10 mg/day) in the initial three months. NSAID dose change or prednison addition to treatment qualified for lack of efficacy in the post hoc analysis. Paracetamol (<1 g/day), but no intra-articular or intralesional injections, was allowed for severe pain.

The number of active joints—defined by soft tissue swelling and tenderness when pressing or pain when moving the joints—was the primary outcome variable. Secondary variables included patient and doctor Likert scale assessments of efficacy (marked improvement or improvement, no change, or worsening) and health (very good, good, fair, or bad); pain severity on a 100 mm visual analogue scale; tender joints and entheses counts (excluding the tarsus); mid-foot swelling and tenderness; American College of Rheumatology functional class; ESR; anterior spinal flexion; and duration of morning stiffness. Clinical and laboratory examinations were performed monthly.

Data were analysed on the basis of the intention to treat principle. Baseline versus final values were analysed by paired t test or Wilcoxon’s signed rank, and SSZ versus placebo by t test or Mann-Whitney test. The significance level was fixed at p<0.05.

Table 1

<table>
<thead>
<tr>
<th></th>
<th>Sulfasalazine (n=17)</th>
<th>Placebo (n=16)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Final</td>
</tr>
<tr>
<td>Active joints (count)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tender entheses (count)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Areas of foot tenderness (count)</td>
<td>7.3 (4.8)</td>
<td>4.15 (5.6)</td>
</tr>
<tr>
<td>Areas of foot swelling (count)</td>
<td>7.3 (4.8)</td>
<td>4.15 (5.6)</td>
</tr>
<tr>
<td>Pain VAS (0–100 mm)</td>
<td>59.2 (25.2)</td>
<td>32.3 (26.5)</td>
</tr>
<tr>
<td>Morning stiffness (min)</td>
<td>8.3 (14.6)</td>
<td>6.5 (21.7)</td>
</tr>
<tr>
<td>Anterior spinal flexion (cm)</td>
<td>5.5 (1.3)</td>
<td>6.2 (21.4)</td>
</tr>
<tr>
<td>Lumbar pain (No [%] patients)</td>
<td>5 (29)</td>
<td>1 (0)</td>
</tr>
<tr>
<td>Cervical pain (No [%] patients)</td>
<td>3 (18)</td>
<td>0</td>
</tr>
<tr>
<td>Physician efficacy assessment [No [%] patients]</td>
<td>10 (59)</td>
<td>4 (25)</td>
</tr>
<tr>
<td>Improved</td>
<td>3 (18)</td>
<td>10 (63)</td>
</tr>
<tr>
<td>Unchanged</td>
<td>4 (24)</td>
<td>2 (13)</td>
</tr>
<tr>
<td>Patient efficacy assessment [No [%] patients]</td>
<td>11 (65)</td>
<td>4 (25)</td>
</tr>
<tr>
<td>Improved</td>
<td>2 (12)</td>
<td>7 (44)</td>
</tr>
<tr>
<td>Unchanged</td>
<td>4 (25)</td>
<td>5 (31)</td>
</tr>
</tbody>
</table>

VAS, visual analogue scale.

* p=0.03; † p=0.04.
SSZ (n=17) or placebo (n=16). Two patients receiving SSZ and three receiving placebo were lost to follow up; treatment of two more receiving SSZ and eight receiving placebo was prematurely discontinued in the post hoc analysis because of lack of efficacy. The sample size has a post hoc statistical power of 11% for the number of active joints.

RESULTS AND DISCUSSION
Group characteristics—including the proportion with SEA syndrome and AS in each group—were comparable at baseline. Most variables in the SSZ and placebo groups improved significantly, but differences between groups were only significant in the doctor and patient assessments of improvement (table 1) and the number of changes of concomitant treatment (2 v 8; p=0.0026). Four patients receiving SSZ and two receiving placebo had mild or moderate epigastric pain not requiring specific treatment or withdrawal from the study.

Although the lack of further differences between the groups may result from the small number of patients enrolled of restrictions in the inclusion criteria, the high rate placebo response similar to that seen in adult onset SpA studies, and additional factors, including the natural course of the disease, the results of this trial suggest that SSZ may be useful in active juvenile onset SpA.

ACKNOWLEDGEMENT
Supported (in part) by Kabi-Pharmacia, Sweden.

Authors’ affiliations
R Burgos-Vargas, Research Division, Hospital General de Mexico
J Vázquez-Mellado, C Pacheco-Tena, M V Goycochea-Robles, Rheumatology Service, Hospital General de Mexico

A Hernández-Garduño, Department of Clinical Research, Hospital General de Mexico
Correspondence to: Professor R Burgos-Vargas, Dirección de Investigación, Hospital General de Mexico, Dr Balmis 148, México DF 06726; burgosv@attglobal.net
Accepted 16 April 2002

REFERENCES

Leflunomide decreases joint erosions and induces reparative changes in a patient with psoriatic arthritis

M Cuchacovich, L Soto

We read with great interest the article by Scott and colleagues, in which they report radiological improvement or halting of disease progression with leflunomide treatment in a group of patients with rheumatoid arthritis (RA). Leflunomide has also been reported to be effective in some studies including a small group of patients with psoriatic arthritis (PsA), but radiological evolution was not evaluated. We report the case of a patient with PsA who had clinical remission and radiological amelioration after a year with leflunomide treatment. To our knowledge, this is the first evidence that leflunomide may induce reparative changes such as filling of a bone cyst in a patient with PsA.

CASE REPORT
A 37 year old white man presented in August 1997 with a history of pain in the left wrist, right ankle, and both feet during the previous three months. His past history and physical examination were unremarkable except for synovitis in the painful joints and a single well demarcated erythematous hyperkeratotic plaque on the trunk. A dermatologist was consulted and psoriasis vulgaris was confirmed by biopsy.

No crystals were found in synovial fluid obtained from the right ankle. Hand and foot radiographs did not show osteoarticular damage. His rheumatoid factor was negative, haemoglobin, white cell blood count, and serum uric acid levels were normal; the erythrocyte sedimentation rate was 25 mm/1st h. Meclofenamate 100 mg three times a day was started, with good initial clinical response, and the dose was decreased to 100 mg twice daily.

The patient remained stable until February 1998 when he consulted with recurrent joint symptoms. Marked pain and swelling was found in the previously affected joints. Sulfasalazine at a dose of 2 g/day was added to the meclofenamate and the arthritis was controlled after two months of treatment. A new set of radiographs of the hands and feet did not show erosive changes.

He continued receiving the same treatment during the next 18 months, experiencing slight pain in both feet after climbing stairs or standing for long periods. In November 1999 he consulted with a new flare in the left wrist, right sacroiliac joint, and right foot. A new set of foot radiographs (fig 1A) was obtained and showed erosions in the right fifth proximal interphalangeal joint and a subchondral cyst in the fifth metatarsal head. The left foot was radiologically normal.
Methotrexate was added to the treatment, but the patient developed fever and severe diarrhoea after the second dose. Methotrexate was stopped and leflunomide was started in January 2000. He received a three day initial loading dose of 100 mg/day followed by 20 mg daily doses.

With this new schedule the patient had clinical remission of the disease, and meclofenamate was changed to rofecoxib 25 mg/day.

A new set of radiographs (fig 1B) was performed a year later and showed partial filling of the subchondral cyst with bony sclerosis, progressive bone absorption of the erosion in the right fifth interphalangeal joint, and no new erosions.

At the present time the patient’s disease remains inactive, but right foot pain appears after excessive mechanical stress.

**DISCUSSION**

Significant slowing of radiographic disease progression has been described, and reparative changes have been suggested with leflunomide treatment in patients with RA. However, up to now no radiological data are available for patients with PsA.

Our report describes a patient with PsA who developed an erosive disease despite being treated with other disease modifying antirheumatic drugs (DMARDs). After the addition of leflunomide to the treatment for more than one year, a bone cyst of a metatarsal head was seen to have filled.

The main objection for accepting the concept of “radiological joint amelioration” is that some authors argue that “filling in” of bone cysts, when presented in association with joint remodelling, may be an expression of disease progression and not a reparative process. However, in our patient filling of the bone cyst appeared without any evidence of remodelling in the distal articulating surface of the metatarsal head. The metatarsophalangeal joint surface is regular, and the joint space was conserved. In addition, no new erosions were detected.

There is both experimental and clinical evidence to show that reparative reactions occur in patients with RA treated effectively with DMARDs. It has also been reported that functional repairing of articular cartilage can occur if the proper environment is created to promote repair. Leflunomide limits T cell proliferation, enzymatic degradation of bone and cartilage by destructive metalloproteinases, and proinflammatory cytokines such as tumour necrosis factor α, interleukin 1, and interleukin 8. These mechanisms may explain the prevention of structural damage seen with leflunomide in different studies.

In summary, we present radiological evidence that supports the hypothesis that leflunomide may induce reparative changes such as bone cyst filling in a patient with PsA. To confirm this finding it will be necessary to include radiographic scoring methods in future studies of leflunomide efficacy in PsA.

---

**Authors’ affiliations**

M Cuchacovich, L Soto, Rheumatology Section, Department of Medicine, University of Chile Clinical Hospital, Santiago, Chile

Correspondence to: Dr M Cuchacovich, Roberto del Río 978, Providencia, Santiago, Chile; mcuchaco@ns.hospital.uchile.cl

Accepted 6 March 2002

**REFERENCES**


---

**Figure 1** (A) November 1999. Active erosion in the right fifth proximal interphalangeal joint and a subchondral cyst in the fifth metatarsal head (arrow). (B) December 2000. Partial filling of the subchondral cyst, with nearly normal bone structure (arrow), progressive bone absorption of the erosion in the right fifth interphalangeal joint, and no new erosions. The metatarsophalangeal joint surface is regular, and the joint space is conserved.
Fractures of the scapula occur infrequently, with a fracture of the acromion being an even rarer entity. Acromial fractures constitute 9% of fractures of the scapula, which amounts to 3–5% of shoulder girdle injuries.¹ Fractures of the acromion are generally secondary to trauma, with only a few cases of stress fracture having been reported.²⁻⁵ Reports published in English have described stress fractures of the acromion at the base of the acromion extending to the spine of the scapula,² neck of the acromion,³ medial aspect of the acromion,⁴ and the base of the acromion only.⁵ These cases occurred in young to middle aged patients and were associated with a single violent muscle contraction or repetitive subcritical load to the shoulder. We present a case of an atraumatic osteoporotic stress fracture at the base of the acromion associated with chronic rotator cuff tear arthropathy.

CASE REPORT
The patient, an 82 year old woman, was admitted to the medical ward with heart failure and varicose ulcers. She was referred to the orthopaedic department because of a three day history of left shoulder pain without trauma. She was mostly wheelchair bound but did walk indoors with a Zimmer frame.

Examination showed mild tenderness and crepitus at the base of the acromion where a fracture gap could be palpated. Active shoulder movements were restricted to 90° of both flexion and abduction. She also had a senile osteoporotic kyphosis of her thoracic spine. Anteroposterior and axillary radiographs of the shoulder showed a displaced fracture of the base of the acromion with superior subluxation of the head of the humerus, suggesting chronic rotator cuff tear arthropathy (figs 1 and 2). A radiograph of her spine confirmed the osteoporotic kyphosis of the thoracic vertebrae. Blood tests including full blood count, erythrocyte sedimentation rate (ESR), bone biochemistry, and myeloma screen were normal. She was treated conservatively in a broad arm sling with gradual mobilisation as her pain subsided. She recovered nearly full movements of her shoulder in four weeks. A follow up x-ray examination at six months showed a non-union of the fracture, which was not painful.

DISCUSSION
Osteoporotic fractures without a history of trauma usually occur in the legs, pelvis or spine and rarely in the arms. Repetitive subcritical trauma or single violent muscular pulls have occasionally been associated with fractures of the acromion.⁶ Of the previous four cases of a similar type of injury reported, two were professional sports players,¹ one was a car mechanic who felt a sudden crack in his shoulder while applying torque with a screwdriver,³ and the fourth was a woman playing golf, who suddenly felt acute pain in her shoulder as she hit the ball.² It was not possible to correlate our patient’s injury with any trauma, indeed she recalled waking up in the morning with sudden pain, which gradually got worse. Dennis et al reported three cases of stress fracture of the anterior impingement zone of the acromion.⁷ All three patients had severe rotator cuff arthropathy and two had steroid dependent rheumatoid arthritis.³ Surgical excision of the fragments was carried out in all three of his patients when conservative treatment had failed, with one patient eventually requiring shoulder replacement. Pain improved in the other two patients, but there was no improvement in the range of motion. All the fractures reported united after conservative treatment except in the series reported by Dennis et al.⁷

It is sometimes difficult to visualise this fracture without adequate penetration of radiographs in the appropriate plane. These fractures are best visualised in the axillary view in our opinion (fig 2). All previous cases have been either linear undisplaced fractures or diagnosed by an isotope bone scan. One case did show sclerosis at the base of the acromial arch on x-ray examination, which on subsequent bone scan was confirmed to be a fracture.³ We believe that abnormal pressure from the humeral head on the acromion, due to the rotator cuff arthropathy, leads to excessive movement at the fracture site causing a non-union of the fractured acromion.

Shoulder pain is a common complaint in elderly people. A stress fracture of the acromion should be considered in patients with chronic rotator cuff tear arthropathy who
have osteoporosis and whose shoulder pain increases spontaneously. Routine use of good quality axillary radiographs in such patients should lead to a higher rate of diagnosis of such injuries.

Authors’ affiliations
N Roy, M G Smith, L G H Jacobs, The Royal Oldham Hospital, Rochdale Road, Oldham OL1 2JH, UK
Correspondence to: Mr M G Smith, Grove Cottage, 18 Grove Lane, Didsbury, M20 6UE, UK, mgsmith@doctors.org.uk
Accepted 4 April 2002

CASE REPORT

Here, we report a severe vasculitic episode in a patient with primary Sjögren’s syndrome (pSS) and heterozygous α1 antitrypsin deficiency.

The patient, a white woman, was diagnosed with pSS at the age of 44 years. The diagnosis fulfilled the Copenhagen and the European community classification criteria for pSS. Five years after the start of sicca symptoms, arthritis suddenly appeared in the knee and ankle joints, as well as purpuric eruption on the lower legs. Laboratory studies showed a raised erythrocyte sedimentation rate (ESR 78 mm/1st h) and C reactive protein (CRP 42 mg/l; normal <10 mg/l) and on urine analysis proteinuria and microscopic haematuria. Oral prednisolone treatment was started, but a week later the patient suddenly experienced headache and loss of vision. Decreased wakefulness and generalised seizures ensued. Computed tomography of the brain showed three small haemorrhagic cortical infarctions, and an eye examination disclosed cortical blindness (complete visual loss with normal light reflexes). Two of three tests for circulating immune complexes were positive, and measurement of complement factors C3 and C4 showed relative deficiency of C4. C4 isotyping disclosed the phenotype C4A3B1. Positive serological tests (rheumatoid factor, antinuclear antibodies, and anti-SSA/SSB) were unchanged compared with before the acute episode, while an ANCA test and a test for antiphospholipid antibodies were negative.

Intravenous (IV) injection of methylprednisolone and bolus IV cyclophosphamide produced a rapid response and the arthritis disappeared and eyesight gradually improved. Urine findings and ESR/CRP normalised. Oral prednisolone and intermittent IV cyclophosphamide were given for one year. A retrospective chart review has on two separate occasions shown low plasma levels of α1 antitrypsin (0.7 and 0.81 g/l, respectively; normal 0.9–1.7 g/l). Also, during the inflammatory episode, α1 antitrypsin levels remained normal, while other acute phase proteins were raised. Therefore a genetically determined heterozygous α1 antitrypsin deficiency was suspected. This was confirmed by α1 antitrypsin phenotyping using monoclonal antibody specific for the PiZ mutant in an enzyme linked immunosorbent assay (ELISA). Isoelectric focusing confirmed the PiMZ phenotype. The frequency of PiZ heterozygosity in the Swedish general population is 0.047. The diagnosis of vasculitis in this patient was not verified by biopsy, but the clinical evidence is compelling. The α1 antitrypsin deficiency in this patient is possibly related to the severe systemic vasculitis. Low levels of complement factor C4 have been reported in association with deficient elimination of circulating immune complexes in Sjögren’s syndrome. In the present case the relative deficiency of C4, in addition to α1 antitrypsin deficiency, may hypothetically have contributed to an increased risk of immune complex mediated vasculitis.

DISCUSSION

The clinician should be observant about low levels of α1 antitrypsin in patients with vasculitis because they may indicate a poor prognosis. α1 Antitrypsin is an acute phase protein and therefore deficiency might be masked by the presence of inflammation. As in this case, normal α1 antitrypsin levels may be consistent with deficiency of the protein. For definitive diagnosis it is essential to perform phenotype identification.

ACKNOWLEDGEMENT

We thank Dr I Truedsson, Department of Microbiology, University Hospital, Lund, Sweden, for performing the C4 isotyping.

REFERENCES


α1 Antitrypsin deficiency in a patient with systemic vasculitis and primary Sjögren’s syndrome

F D Lindström, T Skogh, I M C Lundström

Ann Rheum Dis 2002;61:945–946
Authors’ affiliations
F D Lindström, T Skogh, Division of Rheumatology, Department of Molecular and Clinical Medicine, Faculty of Health Sciences, University Hospital, 581 85 Linköping, Sweden
I M C Lundström, Department of Oral Medicine, University Hospital, 581 85 Linköping, Sweden

Correspondence to: Dr F D Lindström; folke.lindstrom@swipnet.se

Accepted 4 March 2002

REFERENCES


A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies

R Burgos-Vargas, J Vázquez-Mellado, C Pacheco-Tena, A Hernández-Garduño and M V Goycochea-Robles

Ann Rheum Dis 2002 61: 941-942
doi: 10.1136/ard.61.10.941

Updated information and services can be found at:
http://ard.bmj.com/content/61/10/941

These include:

References
This article cites 10 articles, 1 of which you can access for free at:
http://ard.bmj.com/content/61/10/941#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/